Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed

Eli Lilly blamed the misses on drug wholesalers cutting inventory of Zepbound and Mounjaro.

Business - CNBC - 5 hours ago

Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.

Business - MarketWatch - 6 hours ago

Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

US group revises down upper end of full-year revenue estimates

Business - Financial Times - 13 hours ago

Eli Lilly to trial use of weight loss drugs to combat unemployment in UK

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.

Business - CNBC - October 15

Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.

Eli Lilly's quarter was messy. What to do with the stock is more clear-cut

We're upgrading our rating on the drugmaker to a buy-equivalent 1.

Business - CNBC - 6 hours ago

Lilly's weight loss drug shortage deemed over, but hurdles remain

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Medicare enrollment is often just one big sales pitch. Here’s where to get help.

Sales pitches are often biased, choices can be overwhelming and impartial help is not equally available to all.

Business - MarketWatch - Yesterday

L’Oréal sales disappoint due to weak Chinese demand

Revenue at world’s biggest beauty company grew 3.4 per cent in third quarter, when analysts expected 6 per cent

Business - Financial Times - October 22

Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase manufacturing capacity.

Business - CNBC - 5 hours ago

Jim Cramer looks at what to do with Eli Lilly, AMD shares after their big slides on earnings

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

Business - CNBC - 10 hours ago

Here’s How the U.S. Is Handling the IV Fluid Shortage Caused by Helene

The U.S. government and its agencies are providing recovery assistance and granting import waivers to Baxter International, which makes 60 percent of U.S. IV liquids, after its North Carolina ...

Business - Inc. - October 16

Chipotle misses revenue estimates as same-store sales growth disappoints

Chipotle's same-store sales rose 6% in the third quarter, just missing Wall Street's expectations.

Business - CNBC - 12 hours ago

ASML share plunge wipes over $50 billion off Dutch chip giant's value

ASML published its third-quarter earnings Tuesday, a day earlier than expected.

Business - CNBC - October 16

'Joker: Folie a Deux' is this year's latest box-office flop. Here's what else has disappointed

Warner Bros.' "Joker: Folie a Deux" is not the only blockbuster-budgeted film to fall flat at the box office this year.

Business - CNBC - October 18

Why GM’s Mary Barra Still Believes in EVs, Despite Slow Sales

Mary Barra, G.M.’s chief executive, said that the company had fixed battery-manufacturing problems and that its electric vehicles would soon be profitable.

Business - The New York Times - October 17

‘Pod Save America’ Won’t Quit

The hosts of the political podcast have outlasted the wave of anti-Trump #Resistance that made it popular. That’s where things get complicated.

Lifestyle - The New York Times - October 17

Latest in Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed